Guarneri V, Conte PF: The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004, 31 (Suppl 1): S149-161. 10.1007/s00259-004-1538-5.
Article
PubMed
Google Scholar
Lopez E, Nunez MI, Guerrero MR, del Moral R, de Dios Luna J, del Mar Rodriguez M, Valenzuela MT, Villalobos M, Ruiz de Almodovar JM: Breast cancer acute radiotherapy morbidity evaluated by different scoring systems. Breast Cancer Res Treat. 2002, 73 (2): 127-134. 10.1023/A:1015296607061.
Article
CAS
PubMed
Google Scholar
Pinar B, Lara PC, Lloret M, Bordon E, Nunez MI, Villalobos M, Guerrero R, Luna JD, Ruiz de Almodovar JM: Radiation-induced DNA damage as a predictor of long-term toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Res. 2007, 168 (4): 415-422. 10.1667/RR0746.1.
Article
CAS
PubMed
Google Scholar
Ruiz-Garcia J, Ruiz de Almodovar JM, Olea N, Pedraza V: Thyroglobulin level as a predictive factor of tumoral recurrence in differentiated thyroid cancer. J Nucl Med. 1991, 32 (3): 395-398.
CAS
PubMed
Google Scholar
Stearns V, Yamauchi H, Hayes DF: Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat. 1998, 52 (1-3): 239-259. 10.1023/A:1006137619153.
Article
CAS
PubMed
Google Scholar
Esteller M: Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol. 2005, 205 (2): 172-180. 10.1002/path.1707.
Article
CAS
PubMed
Google Scholar
Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG: Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med. 1997, 75 (6): 429-439. 10.1007/s001090050128.
Article
CAS
PubMed
Google Scholar
Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A, Mao JH, Balmain A, Cano A, Esteller M: A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004, 64 (16): 5527-5534. 10.1158/0008-5472.CAN-03-4061.
Article
CAS
PubMed
Google Scholar
Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E: Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res. 2004, 10 (18 Pt 1): 5998-6005. 10.1158/1078-0432.CCR-04-0667.
Article
CAS
PubMed
Google Scholar
Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, Espana P, Bonilla F: Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004, 41 (2): 117-124. 10.1002/gcc.20062.
Article
CAS
PubMed
Google Scholar
Martinez-Galan J, Torres B, Del Moral R, Munoz-Gamez JA, Martin-Oliva D, Villalobos M, Nunez MI, Luna J de D, Oliver FJ, Ruiz de Almodovar JM: Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther. 2008, 7 (6): 958-965. 10.4161/cbt.7.6.5966.
Article
CAS
PubMed
Google Scholar
Auwera Van der I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer. 2009, 100 (8): 1277-1286. 10.1038/sj.bjc.6605013.
Article
PubMed
PubMed Central
Google Scholar
Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005, 2 (Suppl 1): S4-11. 10.1038/ncponc0354.
Article
CAS
PubMed
Google Scholar
Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004, 64 (11): 3807-3813. 10.1158/0008-5472.CAN-03-3852.
Article
CAS
PubMed
Google Scholar
Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S: Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 2001, 61 (6): 2782-2787.
CAS
PubMed
Google Scholar
Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S: Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet. 2001, 357 (9265): 1335-1336. 10.1016/S0140-6736(00)04501-3.
Article
CAS
PubMed
Google Scholar
Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P: DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer. 2003, 107 (6): 970-975. 10.1002/ijc.11508.
Article
CAS
PubMed
Google Scholar
Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P: Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008, 14 (7): 1938-1946. 10.1158/1078-0432.CCR-07-4082.
Article
CAS
PubMed
PubMed Central
Google Scholar
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996, 93 (18): 9821-9826. 10.1073/pnas.93.18.9821.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA. 2000, 97 (11): 6049-6054. 10.1073/pnas.100566997.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S, Dahiya R: Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst. 2002, 94 (5): 384-390.
Article
CAS
PubMed
Google Scholar
Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB: Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008, 5 (5): e114-10.1371/journal.pmed.0050114.
Article
PubMed
PubMed Central
Google Scholar
Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene. 2001, 20 (26): 3348-3353. 10.1038/sj.onc.1204438.
Article
CAS
PubMed
Google Scholar
Jeronimo C, Monteiro P, Henrique R, Dinis-Ribeiro M, Costa I, Costa VL, Filipe L, Carvalho AL, Hoque MO, Pais I, Leal C, Teixeira MR, Sidransky D: Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat. 2008, 109 (1): 27-34. 10.1007/s10549-007-9620-x.
Article
CAS
PubMed
Google Scholar
Jacinto FV, Esteller M: Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis. 2007, 22 (4): 247-253. 10.1093/mutage/gem009.
Article
CAS
PubMed
Google Scholar
Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB: 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007, 446 (7133): 329-332. 10.1038/nature05584.
Article
CAS
PubMed
Google Scholar
Valenzuela MT, Mateos S, Ruiz de Almodovar JM, McMillan TJ: Variation in sensitizing effect of caffeine in human tumour cell lines after gamma-irradiation. Radiother Oncol. 2000, 54 (3): 261-271. 10.1016/S0167-8140(99)00180-2.
Article
CAS
PubMed
Google Scholar
Valenzuela MT, Guerrero R, Nunez MI, Ruiz De Almodovar JM, Sarker M, de Murcia G, Oliver FJ: PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene. 2002, 21 (7): 1108-1116. 10.1038/sj.onc.1205169.
Article
CAS
PubMed
Google Scholar
Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S: Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002, 417 (6891): 871-875. 10.1038/nature00826.
Article
CAS
PubMed
Google Scholar
Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y: Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 2007, 9 (4): R57-10.1186/bcr1762.
Article
PubMed
PubMed Central
Google Scholar
Dillon RL, Brown ST, Ling C, Shioda T, Muller WJ: An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer. Mol Cell Biol. 2007, 27 (24): 8648-8657. 10.1128/MCB.00866-07.
Article
CAS
PubMed
PubMed Central
Google Scholar
Niemantsverdriet M, Wagner K, Visser M, Backendorf C: Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene. 2008, 27 (9): 1315-1319. 10.1038/sj.onc.1210742.
Article
CAS
PubMed
Google Scholar
Wilker EW, Grant RA, Artim SC, Yaffe MB: A structural basis for 14-3-3sigma functional specificity. J Biol Chem. 2005, 280 (19): 18891-18898. 10.1074/jbc.M500982200.
Article
CAS
PubMed
Google Scholar
Chu K, Teele N, Dewey MW, Albright N, Dewey WC: Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and clonogenic survival in irradiated 14-3-3sigma and CDKN1A (p21) knockout cell lines. Radiat Res. 2004, 162 (3): 270-286. 10.1667/RR3221.
Article
CAS
PubMed
Google Scholar
Rajagopalan S, Sade RS, Townsley FM, Fersht AR: Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoforms. Nucleic Acids Res. 38 (3): 893-906. 10.1093/nar/gkp1041.
Schumacher B, Mondry J, Thiel P, Weyand M, Ottmann C: Structure of the p53 C-terminus bound to 14-3-3: Implications for stabilization of the p53 tetramer. FEBS Lett. 2010, 584: 1443-8. 10.1016/j.febslet.2010.02.065.
Article
CAS
PubMed
Google Scholar
Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, et al: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene. 2000, 19 (46): 5298-5302. 10.1038/sj.onc.1203898.
Article
CAS
PubMed
Google Scholar
Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D, Medema R, Kroemer G: The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene. 2004, 23 (25): 4353-4361. 10.1038/sj.onc.1207573.
Article
CAS
PubMed
Google Scholar
Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, Guo Y: Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res. 2008, 14 (21): 7050-7059. 10.1158/1078-0432.CCR-08-0520.
Article
CAS
PubMed
Google Scholar
Rodenhiser DI: Epigenetic contributions to cancer metastasis. Clin Exp Metastasis. 2009, 26 (1): 5-18. 10.1007/s10585-008-9166-2.
Article
CAS
PubMed
Google Scholar
Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM: Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res. 2005, 11 (1): 166-172.
CAS
PubMed
Google Scholar
Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D: 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res. 2008, 68 (6): 1760-1767. 10.1158/0008-5472.CAN-07-3177.
Article
CAS
PubMed
Google Scholar
Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D: 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 2009, 69 (8): 3425-3432. 10.1158/0008-5472.CAN-08-2765.
Article
CAS
PubMed
PubMed Central
Google Scholar
Issa JP: Age-related epigenetic changes and the immune system. Clin Immunol. 2003, 109 (1): 103-108. 10.1016/S1521-6616(03)00203-1.
Article
CAS
PubMed
Google Scholar
Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008, 26 (12): 1987-1992. 10.1200/JCO.2007.10.8407.
Article
CAS
PubMed
Google Scholar